These findings are consistent with our previously published work using vascular endothelial growth factor A165b, angiopoietin-1, and an MMP2/9 inhibitor where, in each case, GEnGlx restoration successfully reduced glomerular permeability in early DN (30, 46, 47). This evidence concerns the gene MMP2 and liver dysplastic nodule.